KRYS
Krystal Biotech, Inc.
Biotechnology · Healthcare · United States
328.34
close · 2026-08-13
value
18
cheaper than peers18
quality
96
stronger fundamentals96
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 21.94× | 37 |
| price to book | 7.57× | 33 |
| EV to EBITDA | 43.73× | 21 |
| forward P/E | 34.10× | 21 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 49.0% | 96 |
| debt to equity | 0.7% | 96 |
| return on equity | 20.1% | 81 |
| revenue growth | 24.1% | 47 |
4 of 4 measures available
Facts
| market cap | $10B |
| free cash flow | $151.7M |
| employees | 295 |
| first trade | 2017-09-20 |
| next earnings | 2026-08-03 |
| fundamentals updated | 2026-08-07 |